Clinical and pharmacologic experience with dibromodulcitol (NSC-104800). A new antitumor agent.
D000328:Adult; D000368:Aged; D000438:Alcohols / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001966:Bromine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008297:Male; D008353:Mannitol / Q000627:therapeutic use; D051379:Mice; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D051381:Rats; D013237:Stereoisomerism
D000438:Alcohols; D000970:Antineoplastic Agents; D008353:Mannitol; D001966:Bromine